Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

Inclusion Criteria: * Males or females * Presents with at least 2 and up to 5 clinically visible SH lesions * Understands that 1 lesion will remain untreated to act as a reference * Lesions must measure no greater than 2.5 x 2.5 at the outside margin * Wishes to have at least 1 and perhaps 2 NPS treatments to each study lesion * Selection of the non-treated reference lesion will be randomly identified * Willing to return for 4 or 5 total study visits at specified intervals over 60 or 90 days * Agrees to photographic or other image capture methods of both the treated and untreated lesions. * Agrees to avoid any other treatment to the NPS treated and untreated SH lesions until the end of the NPS study * Has no evidence of active infection in the designated tissue prior to treatment and reports no infection within 90 days * Is not allergic to Lidocaine or Lidocaine-like products Exclusion Criteria: * Presence of Implantable electronic devices that cannot be removed. e.g., pacemaker or automatic defibrillator * Taking medications prescribed for cardiac arrhythmia at any time within 6 months prior to exposure to the NPS device * SH lesions are located within the eye orbit or on the nose * Active infection or history of infection in designated test area within 90 days prior to study initiation * Use of oral steroid and/or retinoid use within the last 12 months * Prior treatment to the identified SH lesions targeted for the study which occurred within 6 months prior to study start * Is known to be immune-compromised and/or received immunosuppressant therapy within 6 months prior to study start * Taking blood thinning medications * Has Insulin dependent diabetes * Is known to be pregnant or lactating female